MiMedx Group, Inc. (NASDAQ:MDXG) Insider Kimberly Maersk-Moller Sells 2,111 Shares

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) insider Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $8.40, for a total transaction of $17,732.40. Following the transaction, the insider now owns 265,271 shares in the company, valued at approximately $2,228,276.40. The trade was a 0.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

MiMedx Group Stock Down 1.4 %

Shares of MiMedx Group stock traded down $0.11 on Friday, hitting $7.89. 504,870 shares of the company traded hands, compared to its average volume of 711,996. The company has a 50-day moving average price of $8.60 and a 200 day moving average price of $7.77. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market cap of $1.16 billion, a PE ratio of 14.35 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. The business had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Sell-side analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Remove Ads

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MDXG. Phocas Financial Corp. acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $2,016,000. Paradigm Capital Management Inc. NY raised its position in shares of MiMedx Group by 0.5% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock valued at $45,082,000 after buying an additional 22,131 shares during the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $35,000. Virtus Investment Advisers Inc. acquired a new position in shares of MiMedx Group during the fourth quarter valued at about $335,000. Finally, State of Wyoming raised its position in shares of MiMedx Group by 16.3% during the fourth quarter. State of Wyoming now owns 201,111 shares of the company's stock valued at $1,935,000 after buying an additional 28,230 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.